ARROW® PICC with
Now protect your patient beyond insertion.
With the increase in PICC placements, patient care has seen significant advances. However, PICC's are not without potential serious clinical complications; complications that can occur long after insertion. Not all PICCs are designed or manufactured equally. What's more, some don't offer any kind of protection at all. And when you're doing everything in your power to champion better care, why leave your patient open to serious clinical complications? Expect more from your PICC. Here's why you should consider a catheter that protects long after insertion:
- Chlorag+ard® Technology, a chlorhexidine solution chemically bonded to the catheter surface with a controlled release that provides:
- Antimicrobial protection
- Antithrombogenic protection
- Protection against thrombotic occlusion
- Reduction in phlebitis and intimal hyperplasia
- TaperFree™ catheter design ensures stated French size is consistent between distal and proximal ends to minimize risk of PICC-related vessel thrombosis
- All-in-one ErgoPack® kit, an ergonomically-designed maximal barrier kit that provides defense against known sources of bloodstream infection, reduces procedure time and allows for more efficient insertions
Meet the world's first PICC that's antimicrobial, antithrombogenic and more.
We invite you to learn about the first and only multiple-protection pressure injectable PICC available today. Experience the kind of benefits that help decrease risks from a wide-range of complications:
Catheter-Related Blood Stream Infections (CRBSI) are the 10th leading cause of hospital acquired deaths in the U.S. and the number one clinical concern among PICC-inserting clinicians1
PICC-related vessel thrombosis is the number two clinical concern among PICC-inserting clinicians1 and may lead to serious complications including infection, DVT, PTS and pulmonary embolism
Catheter occlusion is the most common noninfectious complication in the long-term use of central lines2 resulting in delayed patient therapy or use of expensive de-clotting agents
Chlorag+ard® Intimal Hyperplasia protection in action.
The science behind the success.
Chlorag+ard® Technology is an innovation designed and manufactured by experts to help you champion better care. The application of this multi-protection technology involves a proprietary process that actually bonds chlorhexidine to both the internal and external catheter surfaces. This technology ensures a controlled release of chlorhexidine providing:
Chlorag+ard® Technology is designed to reduce microbial colonization of pathogens responsible for causing central line–associated bloodstream infections (CLABSIs).
Both the internal and external surfaces are treated with Chlorag+ard® Technology
Proven 99.99% colonization reduction against gram-positive and gram-negative bacteria and fungi, including pathogens such as MRSA, VRE, Escherichia coli, Candida albicans, and Acinetobacter baumannii for at least 30 days3
Chlorag+ard® Technology provides an antithrombogenic effect on catheter surfaces due to the chlorhexidine coating eluting slowly over time. Chlorag+ard® Technology reduces thrombus accumulation on catheter surfaces due to thrombin inhibition by chlorhexidine. Inhibition of thrombin does not allow the final step of the common pathway-the conversion of soluble Fibrinogen to Fibrin slot.
An in vivo study has shown a 61% reduction in thrombus accumulation on catheter surfaces after 30 days4
When challenged with infection, an in vivo study has shown a 92% reduction in thrombus accumulation on catheter surfaces after 30 days4
In vitro tests have shown reduction in intraluminal thrombotic occlusion as evidenced by 51% less pressure to clear thrombus or flush5
An in vivo study has demonstrated Chlorag+ard® Technology to provide vessel wall protection by:
Reduction in local irritation and phlebitis4
An average of 72% less intimal hyperplasia after 30 days4
A clinical concern of great importance.
There have been significant enhancements that help clinicians place PICCs – ultrasound guidance, maximal barrier precautions, Modified Seldinger Technique, even tip navigation. But what is being done to help clinicians protect patients after insertion? Fact is, 72% of infections occur after 5 days9, many via intraluminal contamination. Here is why you should consider the multiple protection of ARROW® PICC with Chlorag+ard® Technology:
- Extra- and intraluminal protection from tip to hub helps defend against different sources of blood stream infection–providing powerful protection beyond insertion
- Intraluminal protection reduces microbial colonization along the entire fluid pathway, important since 72% of central-line related infections occur after five days9
Aiming to attain and sustain your goal of Zero CLABSIs
You have a choice. In stark contrast to unprotected PICCs, ARROW® PICC with Chlorag+ard® Technology offers powerful continuous protection for at least 30 days. This is something you can bring to all your patients today. The reasons for doing so are compelling:
- Proven 99.99% colonization reduction against gram + and gram - bacterial and fungal pathogens
- Extra and intraluminal protection from tip to hub
helps defend against colonization of the catheter surfaces
Chlorag+ard® Technology is proven effective against the following pathogens responsible for Healthcare-Associated Infections.
Chlorag+ard® Technology raises protection to a new standard by achieving a 4-log reduction with only 1 in 10,000 surviving organisms for at least 30 days12
Catheter-related blood stream infection is the leading cause of hospital acquired infections and is associated with substantial morbidity and mortality8
In a 2006 CVC meta-analysis, hospitalized patients with PICCs had similar rates of BSI to those with uncoated CVCs - 2.1/1000 catheter days compared to 2.7/1000 catheter days7
Costs associated with one occurrence of a CRBSI are $32,2548 with an attributable mortality rate of 12% to 25%10
CRBSI occurs from colonization of the extraluminal or intraluminal pathway
Colonization of CVCs is a precursor to CRBSI11
PICC-Related Thrombosis and Thrombotic Occlusion
PICC-related thrombosis and thrombotic occlusion.
Two complications too many.
We applaud the amount of research and funding that's been focused on insertion technologies. It's true, we've made quantum leaps forward. But what about the more common risks, like thrombosis and occlusion post-insertion? Even in the hands of the most experienced and expert clinician, the complications from these two, post-insertion, can drastically impact patient care. It's time we all reduced these risks with a PICC that protects patients on multiple levels. ARROW® PICC with Chlorag+ard® Technology is yet another step forward in championing better care and aspiring to a world with zero complications.
- An in vivo study has shown a 61% reduction in thrombus accumulation on catheter surfaces after 30 days4
- When challenged with infection, an in vivo study has shown a 92% reduction in thrombus accumulation on catheter surfaces after 30 days4
- Reduction in intraluminal thrombotic occlusion as evidenced by 51% less pressure to clear thrombus or flush5
- Reported occurrence of PICC-associated symptomatic vessel thrombosis ranges from
- Reported asymptomatic thrombosis occurs up to 38%14
- Measures for preventing arm deep vein thrombosis (DVT) in patients with cancer should be considered as a first-line aim for Oncologists15
- A correlation between upper extremity vessel thrombosis and bloodstream infection has been reported16,17
- When DVT does occur, it has a significant financial impact with an average cost of $11,957 per incident. DVT-related cost of care can include diagnostic testing, treatment medications, laboratory testing, catheter replacement, professional fees as well as consequences associated with exacerbation of the thrombotic event18
- Other potentially serious complications such as superior vena cava syndrome, pulmonary embolus (PE), and post thrombotic syndrome (PTS) also contribute to increased morbidity and mortality
- Catheter occlusion is the most common noninfectious complication in the long-term use of central lines, with up to 33% becoming occluded19,20
- Causes include mechanical issues, chemical precipitates or thrombotic obstructions. Approximately 58% of catheter occlusions are due to thrombotic occlusion21
The average cost of de-clotting a catheter occlusion is $128.89–coupled with delays in patient therapy, increased risk of device related infection, and increased length of stay make occlusions a significant clinical risk12
Lessen the worry of thrombosis and occlusion.
Gain back the peace of mind.
When it comes to fighting vessel thrombosis and thrombotic occlusion, there's a better option available to you. One that actually helps reduce the occurrence of these complications in the first place. Contrary to unprotected PICCs, the ARROW® PICC with Chlorag+ard® Technology provides a special antithrombogenic effect on internal and external catheter surfaces. This is a direct result of the chlorhexidine eluting slowly over time.Back to Top View Citations
Phlebitis and Intimal Hyperplasia
Chlorag+ard® Intimal Hyperplasia protection in action.
Chlorag+ard® Technology has demonstrated vessel wall protection by reducing phlebitis and intimal hyperplasia4
Phlebitis and intimal hyperplasia are consequences linked to trauma and/or injury to the vessel wall. In response to endothelial injury, smooth muscle cells migrate from the media to the intima and deposit extracellular matrix, causing intimal thickening. This reduction in the lumen of the vein may lead to reduced flow, venous occlusion or stenosis22. Additional studies suggest that intimal hyperplasia may actually be organized thrombus22.
Phlebitis and intimal hyperplasia
- In the upper extremity, the most common causes of venous stenosis are intimal hyperplasia, external compression to the vessel and the placement of central venous catheters23
- Intimal hyperplasia can be minimized by limiting the extent of endothelial injury24
Chlorag+ard® Technology works by slowly eluting chlorhexidine over time. This action helps to resist platelet adhesion and may suppress release of growth factors such as platelet derived growth factors. Chlorag+ard® Technology causes less injury to the vessel wall as evidenced by:
- Reduction in local irritation and phlebitis4
- An average of 72% less intimal hyperplasia after 30 days4
Product Overview and ErgoPack® System
Product Overview and ErgoPack® System
The details on a multi-protection PICC that leaves no
As a champion of better care, we understand every detail must boost function. No amount of intelligence is spared to improve outcomes for you and your patients. The achievements we built into this catheter, both inside and out, help make it the only multiple-protection pressure-injectable PICC on the market today. Yes, it works the instant you do — keeping patients protected immediately after insertion and well beyond. Now you can implement a smarter set of innovations that transform how you protect your patients, including:
- BLUE FLEX TIP®: Softer contoured design enhances maneuverability while minimizing vessel trauma
- STAGGERED EXIT PORTS: Reduces the risk of mixing incompatible medications that can create precipitate
- SECONDSITE™ ADJUSTABLE HUB: Fastens catheter at insertion site anywhere along catheter body
- TAPERFREE™ CATHETER DESIGN: Minimizes risk of catheter-related thrombosis and ensures stated French size is consistent between distal and proximal ends
Multiple-protection now comes in a multitude of products.
No matter the patient, no matter the situation, ARROW® PICC with Chlorag+ard® Technology comes in a size and setting just for you.
Experience form and function.
Streamlined and ergonomic, ARROW® ErgoPack® is a Maximal Barrier System designed to benefit you every step of the way. The all-inclusive layout is incredibly intuitive and easy-to-use. Plus, the systematic design not only saves time for the clinician, but also provides essential tools that offer defense against possible sources of Central Line-Associated Bloodstream Infections. To better serve you, our kits meet guidelines and recommendations from organizations to reduce the risk of CLABSI and sharps injuries. Yes, we never stop thinking.Back to Top View Citations